Evidence map›Paper›PMID 29203663›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Selected reaction monitoring approach for validating peptide biomarkers.

Qing Wang, Ming Zhang, Tyler Tomita, Joshua T Vogelstein, Shibin Zhou, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein

Open access · bronzeAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Proteomics in Inherited Metabolic Disorders.International journal of molecular sciences · 2022
    Review
  9. [Research advances of metabolomics in early diagnosis of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Direct Detection and Quantification of Neoantigens.Cancer immunology research · 2019
    Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qing WangLudwig Center, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287; qing@jhmi.edu bertvog@gmail.com.
Ming ZhangLudwig Center, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287.
Tyler TomitaDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218.
Joshua T VogelsteinDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218.
Shibin ZhouLudwig Center, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287.
Nickolas PapadopoulosLudwig Center, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287.
Kenneth W KinzlerLudwig Center, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287.
Bert VogelsteinLudwig Center, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287; qing@jhmi.edu bertvog@gmail.com.
Sidney Kimmel Cancer Center · USHoward Hughes Medical Institute · USJohns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NIGMS NIH HHS T32 GM007309
6 · The paper itself

Abstract

We here describe a selected reaction monitoring (SRM)-based approach for the discovery and validation of peptide biomarkers for cancer. The first stage of this approach is the direct identification of candidate peptides through comparison of proteolytic peptides derived from the plasma of cancer patients or healthy individuals. Several hundred candidate peptides were identified through this method, providing challenges for choosing and validating the small number of peptides that might prove diagnostically useful. To accomplish this validation, we used 2D chromatography coupled with SRM of candidate peptides. We applied this approach, called sequential analysis of fractionated eluates by SRM (SAFE-SRM), to plasma from cancer patients and discovered two peptides encoded by the peptidyl-prolyl

Indexed as

Biomarkers, TumorCase-Control StudiesColorectal NeoplasmsCyclophilin AFemaleHumansMolecular Diagnostic TechniquesOvarian NeoplasmsPancreatic NeoplasmsPeptidesProteomicsSensitivity and SpecificityBiomarkers, TumorCyclophilin APeptidescancer diagnosticsclinical proteomicspeptide biomarkerplasma biomarkerselected reaction monitoring

Identifiers

PMID29203663
PMCPMC5754789
OpenAlexW2771855438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.